

# Andrew M Jeremijenko

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2574292/publications.pdf>

Version: 2024-02-01

36  
papers

4,640  
citations

257101

24  
h-index

360668

35  
g-index

70  
all docs

70  
docs citations

70  
times ranked

3832  
citing authors

#	ARTICLE	IF	CITATIONS
1	Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar. <i>New England Journal of Medicine</i> , 2021, 385, e83.	13.9	675
2	Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections. <i>New England Journal of Medicine</i> , 2022, 387, 21-34.	13.9	368
3	Protection against the Omicron Variant from Previous SARS-CoV-2 Infection. <i>New England Journal of Medicine</i> , 2022, 386, 1288-1290.	13.9	356
4	BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar. <i>Nature Medicine</i> , 2021, 27, 2136-2143.	15.2	346
5	mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar. <i>Nature Medicine</i> , 2021, 27, 1614-1621.	15.2	337
6	Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar. <i>New England Journal of Medicine</i> , 2022, 386, 1804-1816.	13.9	311
7	Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar. <i>Nature Communications</i> , 2022, 13, .	5.8	188
8	Assessment of the Risk of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Reinfection in an Intense Reexposure Setting. <i>Clinical Infectious Diseases</i> , 2021, 73, e1830-e1840.	2.9	154
9	SARS-CoV-2 antibody-positivity protects against reinfection for at least seven months with 95% efficacy. <i>EClinicalMedicine</i> , 2021, 35, 100861.	3.2	153
10	Association of Prior SARS-CoV-2 Infection With Risk of Breakthrough Infection Following mRNA Vaccination in Qatar. <i>JAMA - Journal of the American Medical Association</i> , 2021, 326, 1930.	3.8	140
11	COVID-19 (SARS-CoV-2) outbreak monitoring using wastewater-based epidemiology in Qatar. <i>Science of the Total Environment</i> , 2021, 774, 145608.	3.9	120
12	Characterizing the Qatar advanced-phase SARS-CoV-2 epidemic. <i>Scientific Reports</i> , 2021, 11, 6233.	1.6	117
13	COVID-19 infection among healthcare workers in a national healthcare system: The Qatar experience. <i>International Journal of Infectious Diseases</i> , 2020, 100, 386-389.	1.5	85
14	SARS-CoV-2 seroprevalence in the urban population of Qatar: An analysis of antibody testing on a sample of 112,941 individuals. <i>IScience</i> , 2021, 24, 102646.	1.9	79
15	Herd Immunity against Severe Acute Respiratory Syndrome Coronavirus 2 Infection in 10 Communities, Qatar. <i>Emerging Infectious Diseases</i> , 2021, 27, 1343-1352.	2.0	74
16	Mathematical modeling of the SARS-CoV-2 epidemic in Qatar and its impact on the national response to COVID-19. <i>Journal of Global Health</i> , 2021, 11, 05005.	1.2	71
17	Pfizer-BioNTech mRNA BNT162b2 Covid-19 vaccine protection against variants of concern after one versus two doses. <i>Journal of Travel Medicine</i> , 2021, 28, .	1.4	69
18	SARS-CoV-2 Infection Is at Herd Immunity in the Majority Segment of the Population of Qatar. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab221.	0.4	58

#	ARTICLE	IF	CITATIONS
19	One Year of SARS-CoV-2: Genomic Characterization of COVID-19 Outbreak in Qatar. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 768883.	1.8	56
20	Introduction and expansion of the SARS-CoV-2 B.1.1.7 variant and reinfections in Qatar: A nationally representative cohort study. <i>PLoS Medicine</i> , 2021, 18, e1003879.	3.9	54
21	Relative infectiousness of SARS-CoV-2 vaccine breakthrough infections, reinfections, and primary infections. <i>Nature Communications</i> , 2022, 13, 532.	5.8	53
22	SARS-CoV-2 infection hospitalization, severity, criticality, and fatality rates in Qatar. <i>Scientific Reports</i> , 2021, 11, 18182.	1.6	49
23	Severity, Criticality, and Fatality of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Beta Variant. <i>Clinical Infectious Diseases</i> , 2022, 75, e1188-e1191.	2.9	38
24	Risk factors for breakthrough SARS-CoV-2 infection in vaccinated healthcare workers. <i>PLoS ONE</i> , 2021, 16, e0258820.	1.1	37
25	Effects of BA.1/BA.2 subvariant, vaccination and prior infection on infectiousness of SARS-CoV-2 omicron infections. <i>Journal of Travel Medicine</i> , 2022, 29, .	1.4	37
26	Epidemiological impact of prioritising SARS-CoV-2 vaccination by antibody status: mathematical modelling analyses. <i>BMJ Innovations</i> , 2021, 7, 327-336.	1.0	27
27	Two prolonged viremic SARS-CoV-2 infections with conserved viral genome for two months. <i>Infection, Genetics and Evolution</i> , 2021, 88, 104684.	1.0	22
28	Analytic comparison between three high-throughput commercial SARS-CoV-2 antibody assays reveals minor discrepancies in a high-incidence population. <i>Scientific Reports</i> , 2021, 11, 11837.	1.6	14
29	SARS-CoV-2 infection in mortuary and cemetery workers. <i>International Journal of Infectious Diseases</i> , 2021, 105, 621-625.	1.5	11
30	Characterizing the effective reproduction number during the COVID-19 pandemic: Insights from Qatar's experience. <i>Journal of Global Health</i> , 2022, 12, 05004.	1.2	7
31	Reporting of RT-PCR cycle threshold (Ct) values during the first wave of COVID-19 in Qatar improved result interpretation in clinical and public health settings. <i>Journal of Medical Microbiology</i> , 2022, 71, .	0.7	7
32	Prevalence and risk factors for SARS-CoV-2 infection and seroprevalence among clinical and non-clinical staff in a national healthcare system. <i>PLoS ONE</i> , 2021, 16, e0257845.	1.1	6
33	Environmental surface contamination with SARS-CoV-2 in professional football clubs. <i>Science and Medicine in Football</i> , 2021, 5, 8-12.	1.0	5
34	SARS-CoV-2 PCR and antibody positivity among school staff at the beginning and end of the first school term. <i>BMC Public Health</i> , 2021, 21, 2070.	1.2	3
35	Assessing the performance of a serological point-of-care test in measuring detectable antibodies against SARS-CoV-2. <i>PLoS ONE</i> , 2022, 17, e0262897.	1.1	1
36	Viral mutations, vaccine effectiveness and rapid tests – COVID-19 risk management in the two largest LNG producing countries, Qatar and Australia. , 2022, 62, S291-S294.		0